|
|
|
|
LEADER |
02830nam a2200493Ia 4500 |
001 |
10.1016-j.jpha.2020.10.004 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 20951779 (ISSN)
|
245 |
1 |
0 |
|a Engineered polymer nanoparticles incorporating L-amino acid groups as affinity reagents for fibrinogen
|
260 |
|
0 |
|b Xi'an Jiaotong University
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.jpha.2020.10.004
|
520 |
3 |
|
|a Synthetic polymer hydrogel nanoparticles (NPs) were developed to function as abiotic affinity reagents for fibrinogen. These NPs were made using both temperature-sensitive N-isopropyl acrylamide (NIPAm) and L-amino acid monomers. Five kinds of L-amino acids were acryloylated to obtain functional monomers: L-phenylalanine (Phe) and L-leucine (Leu) with hydrophobic side chains, L-glutamic acid (Glu) with negative charges, and L-lysine (Lys) and L-arginine (Arg) with positive charges. After incubating the NPs with fibrinogen, γ-globulin, and human serum albumin (HSA) respectively, the NPs that incorporated N-acryloyl-Arg monomers (AArg@NPs) showed the strongest and most specific binding affinity to fibrinogen, when compared with γ-globulin and HSA. Additionally, the fibrinogen-AArg binding model had the best docking scores, and this may be due to the interaction of positively charged AArg@NPs and the negatively charged fibrinogen D domain and the hydrophobic interaction between them. The specific adsorption of AArg@NPs to fibrinogen was also confirmed by the immunoprecipitation assay, as the AArg@NPs selectively trapped the fibrinogen from a human plasma protein mixture. AArg@NPs had a strong selectivity for, and specificity to, fibrinogen and may be developed as a potential human fibrinogen-specific affinity reagent. © 2020 Xi'an Jiaotong University
|
650 |
0 |
4 |
|a Affinity reagent
|
650 |
0 |
4 |
|a amino acid
|
650 |
0 |
4 |
|a Amino-acid monomers
|
650 |
0 |
4 |
|a aqueous solution
|
650 |
0 |
4 |
|a arginine
|
650 |
0 |
4 |
|a Arginine
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a binding affinity
|
650 |
0 |
4 |
|a fibrinogen
|
650 |
0 |
4 |
|a Fibrinogen
|
650 |
0 |
4 |
|a glutamic acid
|
650 |
0 |
4 |
|a human serum albumin
|
650 |
0 |
4 |
|a hydrophobicity
|
650 |
0 |
4 |
|a immunoglobulin
|
650 |
0 |
4 |
|a immunoprecipitation
|
650 |
0 |
4 |
|a incubation time
|
650 |
0 |
4 |
|a leucine
|
650 |
0 |
4 |
|a lysine
|
650 |
0 |
4 |
|a molecular docking
|
650 |
0 |
4 |
|a phenylalanine
|
650 |
0 |
4 |
|a poly(n isopropylacrylamide)
|
650 |
0 |
4 |
|a polymer nanoparticle
|
650 |
0 |
4 |
|a protein domain
|
650 |
0 |
4 |
|a Protein interaction
|
650 |
0 |
4 |
|a Synthetic polymer nanoparticles
|
700 |
1 |
|
|a Liu, R.
|e author
|
700 |
1 |
|
|a Shea, K.J.
|e author
|
700 |
1 |
|
|a Wu, D.
|e author
|
700 |
1 |
|
|a Yu, Q.
|e author
|
700 |
1 |
|
|a Zhu, Q.
|e author
|
700 |
1 |
|
|a Zhu, Y.
|e author
|
773 |
|
|
|t Journal of Pharmaceutical Analysis
|